Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
Shanu Modi(Memorial Sloan Kettering Cancer Center), David Cameron(Corewell Health), Binghe Xu(Chinese Academy of Medical Sciences & Peking Union Medical College), Eriko Tokunaga(National Hospital Organization Kyushu Cancer Center), Junji Tsurutani(SHOWA Medical University), Jean‐Yves Pierga(Université Paris Cité), Naoki Niikura(Tokai University), Patrik Vitazka(Inserm), Dhiraj Gambhire(Inserm), Sung‐Bae Kim(Ulsan College), Nadia Harbeck(Breast Center), Joohyuk Sohn(Yonsei University), Miguel Gil‐Gil(GEICAM – Spanish Breast Cancer Group), Ting Luo(Inserm), Keun Seok Lee(Inserm), Toshinari Yamashita(Kanagawa Prefectural Hospital Organization), Flora Zagouri(National and Kapodistrian University of Athens), William Jacot(Inserm), Peter Schmid(St Bartholomew's Hospital), Tao Sun(Wuhan University), Seock‐Ah Im(Seoul National University), Rinat Yerushalmi(Rabin Medical Center), Andrea Gombos(Inserm), Cristina Saura(Vall d'Hebron Hospital Universitari), Naoto T. Ueno(Breast Cancer Care), Aleix Prat(Hospital Clínic de Barcelona), Hope S. Rugo(City of Hope), Wěi Li(Shougang (China)), Qiang Liu(Sun Yat-sen University), Yibin Wang(Central South University), Xiaojia Wang(Wenzhou Medical University), Yeon Hee Park(Samsung Medical Center), Jasmeet Singh(Inserm), Yee Soo Chae(Kyungpook National University Hospital), Gerold Meinhardt(Daiichi Sankyo (United States)), María Vidal(Inserm), Lotus Yung(Inserm), Halle C. F. Moore(Cleveland Clinic)
Cited by 2,528
Related Papers
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
|The Lancet|2014|4.7k
Pembrolizumab for Early Triple-Negative Breast Cancer
|New England Journal of Medicine|2020|3.1k
Palbociclib and Letrozole in Advanced Breast Cancer
|New England Journal of Medicine|2016|2.9k
Breast cancer
|Nature Reviews Disease Primers|2019|2.9k
Breast cancer
|The Lancet|2016|2.3k